Cingulate Announces Detailed Trial Results from Phase 3 Adult Efficacy and Safety Trial of CTx-1301 (dexmethylphenidate) for ADHD
Portfolio Pulse from Benzinga Newsdesk
Cingulate Inc. (NASDAQ:CING) announced full results from the Phase 3 adult efficacy and safety study of its lead candidate, CTx-1301 (dexmethylphenidate), for the treatment of ADHD. The study did not achieve statistical significance on the primary efficacy endpoint but demonstrated a trend toward significance in improving PERMP scores with CTx-1301 compared to placebo.
September 11, 2023 | 10:01 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Cingulate's Phase 3 trial results for CTx-1301 did not meet the primary efficacy endpoint, which may negatively impact investor sentiment. However, the trend towards improving PERMP scores could be seen as a positive sign.
The failure to meet the primary efficacy endpoint in a Phase 3 trial is typically seen as a negative by investors, as it raises questions about the drug's effectiveness and potential for FDA approval. However, the trend towards improving PERMP scores could be seen as a positive sign, suggesting that the drug may still have potential benefits. This mixed result makes the short-term impact on Cingulate's stock price uncertain.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100